Baker BROS. Advisors LP Acquires 743,075 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 743.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 843,075 shares of the company’s stock after purchasing an additional 743,075 shares during the quarter. CRISPR Therapeutics comprises about 0.4% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 27th biggest position. Baker BROS. Advisors LP owned approximately 0.99% of CRISPR Therapeutics worth $39,608,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after acquiring an additional 46,148 shares in the last quarter. California State Teachers Retirement System grew its holdings in CRISPR Therapeutics by 1.1% during the first quarter. California State Teachers Retirement System now owns 67,901 shares of the company’s stock valued at $4,628,000 after purchasing an additional 710 shares during the last quarter. Cetera Investment Advisers raised its position in shares of CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock valued at $2,324,000 after purchasing an additional 27,915 shares during the period. Cetera Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the first quarter worth $334,000. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of CRISPR Therapeutics by 1.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 40,745 shares of the company’s stock worth $2,807,000 after buying an additional 745 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on CRSP shares. Truist Financial cut their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Stock Up 0.6 %

Shares of CRSP opened at $51.17 on Monday. The company has a 50-day moving average price of $48.13 and a two-hundred day moving average price of $51.58. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of -18.08 and a beta of 1.67. CRISPR Therapeutics AG has a 12 month low of $43.42 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the company earned ($1.41) EPS. Equities research analysts expect that CRISPR Therapeutics AG will post -5.14 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.